ArticleChemical biology & drug design2026
Integrative Multi-Omics and Experimental Validation Define RELB as an Immune-Related Prognostic Driver in Ovarian Cancer.
Article in Chemical biology & drug design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Ovarian cancer (OC) is one of the most aggressive gynecological malignancies worldwide. The tumor microenvironment and transcriptomic alterations play important roles in OC progression and therapeutic response. Integrative bulk and single-cell transcriptomic analyses may facilitate the identification of prognostic biomarkers and potential therapeutic targets. Multi-Omic datasets from TCGA and GEO were analyzed. Immune-related genes were first integrated with survival information and screened using a random survival forest model to identify five core genes. GO/KEGG analyses were performed on differentially expressed genes, while GSEA and GSVA were used to characterize pathways associated with the core genes. Single-cell RNA-seq data were processed to determine cell-type-specific expression patterns. Molecular docking predicted potential gene-drug interactions. CCK-8, Transwell, and flow cytometry assays assessed the functional role of RELB in OC cells. Five core genes-RELB, CXCL9, PI3, TRAC, and CXCL11-were identified through integration of immune-related genes and random survival forest analysis. Drug sensitivity analysis showed that the expression of all five genes was associated with sensitivity to KU-55933. High expression of key genes was associated with altered immune-related features, while CXCL9, CXCL11, and TRAC were positively associated with CD8+ T-cell abundance and cytolytic activity. Single-cell sequencing identified seven cell types, among which CXCL9 and CXCL11 were highly expressed in monocytes, TRAC in T cells, and PI3 in epithelial cells. Molecular docking predicted a potential interaction between PI3 and 6atu-PROGESTERONE, with a binding energy of -6.35 kcal/mol. RELB was highly expressed in OC cells, and its knockdown significantly inhibited cell proliferation, migration, and invasion while promoting apoptosis. This study identifies a five-gene prognostic signature linked to the immune microenvironment in ovarian cancer. Among them, RELB showed a functional role in OC cell malignant phenotypes, supporting its potential as a biomarker and therapeutic target. Computational drug sensitivity and docking analyses provide hypothesis-generating evidence for potential therapeutic associations that require experimental validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.